Systemic sclerosis-associated Sjögren's syndrome and relationship to the limited cutaneous subtype: Results of a prospective study of sicca syndrome in 133 consecutive patients

Arthritis and Rheumatism

Volumn 54, Issue 7, 2006, Pages 2243-2249

  Avouac, J ^a   Sordet, C ^b   Depinay, C ^a   Ardizonne, M ^b   Vacher Lavenu, M C ^a   Sibilia, J ^b   Kahan, A ^a   Allanore, Y ^a,c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c Service de Rhumatologie A ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

CENTROMERE ANTIBODY;

ADULT; AGED; ARTICLE; AUTOIMMUNITY; COMPUTER ASSISTED TOMOGRAPHY; EVALUATION RESEARCH; FEMALE; HISTOPATHOLOGY; HOSPITALIZATION; HUMAN; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SALIVARY GLAND BIOPSY; SIALOADENITIS; SJOEGREN SYNDROME; SKIN DISEASE; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; SYSTEMIC SCLEROSIS;

ADULT; AGED; AUTOANTIBODIES; COMORBIDITY; FEMALE; FIBROSIS; HUMANS; KERATOCONJUNCTIVITIS SICCA; MALE; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES; PULMONARY FIBROSIS; SALIVARY GLANDS; SCLERODERMA, SYSTEMIC; SJOGREN'S SYNDROME;

EID: 33745930239     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21922     Document Type: Article

References (43)

1. Nagy G, Kovacs J, Zeher M, Czirjak L. Analysis of the oral manifestations of systemic sclerosis. Oral Surg Oral Med Oral Pathol 1994;77:141-6.
2. Janin A, Gosselin B, Gosset D, Hatron PY, Sauvezie B. Histological criteria of Sjögren's syndrome in scleroderma. Clin Exp Rheumatol 1989;7:167-9.
3. Alarcon-Segovia D, Ibanez G, Hernandez-Ortiz J, Velazquez-Forero F, Gonzalez-Jimenez Y. Sjögren's syndrome in progressive systemic sclerosis (scleroderma). Am J Med 1974;57:78-85.
4. Cipoletti JF, Buckingham RB, Barnes EL, Peel RL, Mahmood K, Cignetti FE, et al. Sjögren's syndrome in progressive systemic sclerosis. Ann Intern Med 1977;87:535-41.
5. Osial TA Jr, Whiteside TL, Buckingham RB, Singh G, Barnes EL, Pierce JM, et al. Clinical and serologic study of Sjögren's syndrome in patients with progressive systemic sclerosis. Arthritis Rheum 1983;26:500-8.
6. Andonopoulos AP, Drosos AA, Skopouli FN, Moutsopoulos HM. Sjögren's syndrome in rheumatoid arthritis and progressive systemic sclerosis: a comparative study. Clin Exp Rheumatol 1989;7:203-5.
7. Rodnan GP. The natural history of progressive systemic sclerosis (diffuse scleroderma). Bull Rheum Dis 1963;13:301-4.
8. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al, and the European Study Group on Classification Criteria for Sjögren's Syndrome. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8.
9. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol 1988;15:202-5.
10. Georges C, Chassany O, Mouthon L, Tiev K, Toledano C, Meyer O, et al. Validation of French version of the Scleroderma Health Assessment Questionnaire (SSc HAQ). Clin Rheumatol 2005;24:3-10.
11. Valentini G, Medsger TA Jr, Silman AJ, Bombardieri S. Conclusion and identification of the core set of variables to be used in clinical investigations. Clin Exp Rheumatol 2003;21 Suppl 29: S47-8.
12. Allanore Y, Borderie D, Meune C, Cabanes L, Weber S, Ekindjian OG, et al. N-terminal pro-brain natriuretic peptide as a diagnostic marker of early pulmonary artery hypertension in patients with systemic sclerosis and effects of calcium-channel blockers. Arthritis Rheum 2003;48:3503-8.
13. Chisholm DM, Mason DK. Labial salivary gland biopsy in Sjögren's disease. J Clin Pathol 1968;21:656-60.
14. Miyawaki S, Asanuma H, Nishiyama S, Yoshinaga Y. Clinical and serological heterogeneity in patients with anticentromere antibodies. J Rheumatol 2005;32:1488-94.
15. Hebbar M, Janin A, Huglo D, Copin MC, Lafyatis R, Devulder B, et al. Xerostomia in systemic sclerosis: systematic evaluation by salivary scintigraphy and lip biopsy in thirty-four patients. Arthritis Rheum 1994;37:439-41.
16. Hebbar M, Janin A, Lassalle P, Hatron PY, Hachulla E, Tonnel AB, et al. The correlation between salivary endothelial expression of E-selectin and clinical and biological parameters in systemic scleroderma. Rev Med Interne 1998;19:537-41. In French.
17. Hebbar M, Gillot JM, Hachulla E, Lassalle P, Hatron PY, Devulder B, et al. Early expression of E-selectin, tumor necrosis factor a, and mast cell infiltration in the salivary glands of patients with systemic sclerosis. Arthritis Rheum 1996;39:1161-5.
18. Hebbar M, Lassalle P, Janin A, Vanhee D, Bisiau S, Hatron PY, et al. E-selectin expression in salivary endothelial cells and sera from patients with systemic sclerosis: role of resident mast cell-derived tumor necrosis factor a. Arthritis Rheum 1995;38:406-12.
19. Vivino FB, Al-Hashimi I, Khan Z, LeVeque FG, Salisbury PL III, Tran-Johnson TK, et al, for the P92-01 Study Group. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. Arch Intern Med 1999;159:174-81.
20. Fox RI. Sjögren's syndrome: evolving therapies. Expert Opin Investig Drugs 2003;12:247-54.
21. Whaley K, Alspaugh MA. Sjögren's syndrome. In: Kelley WN, Harris ED Jr, Ruddy S, Sledge CB, editors. Textbook of rheumatology. 3rd ed. Philadelphia: WB Saunders; 1985. p. 956-78.
22. Medsger TA Jr. Sjögren's syndrome and systemic sclerosis (scleroderma). In: Talal N, Moutsopoulos HN, Kassam SS, eds. Sjögren's syndrome: clinical and immunological aspects. New York: Springer-Verlag; 1987. p. 182-9.
23. Drosos AA, Andonopoulos AP, Costopoulos JS, Stavropoulos ED, Papadimitriou CS, Moutsopoulos HM. Sjögren's syndrome in progressive systemic sclerosis. J Rheumatol 1988;15:965-8.
24. Gilboe IM, Kvien TK, Uhlig T, Husby G. Sicca symptoms and secondary Sjögren's syndrome in systemic lupus erythematosus: comparison with rheumatoid arthritis and correlation with disease variables. Ann Rheum Dis 2001;60:1103-9.
25. Bell S, Krieg T, Meurer M. Antibodies to Ro/SSA detected by ELISA: correlation with clinical features in systemic scleroderma. Br J Dermatol 1989;121:35-41.
26. Akiyama Y, Tanaka M, Takeishi M, Adachi D, Mimori A, Suzuki T. Clinical, serological and genetic study in patients with CREST syndrome. Intern Med 2000;39:451-6.
27. Vlachoyiannopoulos PG, Drosos AA, Wiik A, Moutsopoulos HM. Patients with anticentromere antibodies: clinical features, diagnoses and evolution. Br J Rheumatol 1993;32:297-301.
28. Moutsopoulos HM, Webber BL, Vlagopoulos TP, Chused TM, Decker JL. Differences in the clinical manifestations of sicca syndrome in the presence and absence of rheumatoid arthritis. Am J Med 1979;66:733-6.
29. Andonopoulos AP, Drosos AA, Skopouli FN, Acritidis NC, Moutsopoulos HM. Secondary Sjögren's syndrome in rheumatoid arthritis. J Rheumatol 1987;14:1098-103.
30. Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005;35:35-42.
31. Chung L, Utz PJ. Antibodies in scleroderma: direct pathogenicity and phenotypic associations. Curr Rheumatol Rep 2004;6:156-63.
32. Fujimoto M, Sato S. B lymphocytes and systemic sclerosis. Curr Opin Rheumatol 2005;17:746-51.
33. Sato S, Fujimoto M, Hasegawa M, Takehara K, Tedder TF. Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis. Mol Immunol 2004;41:1123-33.
34. Whitfield ML, Finlay DR, Murray JI, Troyanskaya OG, Chi JT, Pergamenschikov A, et al. Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci U S A 2003;100:12319-24.
35. Del Prete G, De Carli M, Almerigogna F, Daniel CK, D'Elios MM, Zancuoghi G, et al. Preferential expression of CD30 by human CD4+ T cells producing Th2-type cytokines. FASEB J 1995;9:81-6.
36. Rothermel AL, Gilbert KM, Weigle WO. Differential abilities of Th1 and Th2 to induce polyclonal B cell proliferation. Cell Immunol 1991;135:1-15.
37. Mavalia C, Scaletti C, Romagnani P, Carossino AM, Pignone A, Emmi L, et al. Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis. Am J Pathol 1997;151:1751-8.
38. Ihn H, Yazawa N, Kubo M, Yamane K, Sato S, Fujimoto M, et al. Circulating levels of soluble CD30 are increased in patients with localized scleroderma and correlated with serological and clinical features of the disease. J Rheumatol 2000;27:698-702.
39. Rousser F, Garcia E, Defrance T. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci U S A 1989:1890-3.
40. Oswald JP, Wynn TA, Sher A, James SL. Interleukin 10 inhibits macrophage microbicidal activity by blocking the endogenous production of tumor necrosis factor α required as a costimulatory factor for interferon γ-induced activation. Proc Natl Acad Sci U S A 1992;89:8676-80.
41. Ingegnoli F, Trabattoni D, Saresella M, Fantini F, Clerici M. Distinct immune profiles characterize patients with diffuse or limited systemic sclerosis. Clin Immunol 2003;108:21-8.
42. Marie I, Cordel N, Lenormand B, Hellot MF, Levesque H, Courtois H, et al. Clonal T cells in the blood of patients with systemic sclerosis. Arch Dermatol 2005;141:88-9.
43. Allanore Y, Kahan A. Treatment of systemic sclerosis. Joint Bone Spine 2006. E-pub ahead of print.